The loss of patent exclusivity for cancer drug Gleevec contributed to a 12% sales drop, but the drugmaker expects sales from Entresto and Cosentyx to pick up the slack.
Five things for pharma marketers to know: Monday, February 29, 2016
It’s no secret that speed matters in customer interface. Marc Iskowitz settles into the moderator’s seat to find out how biopharma—an industry not known for moving with rapidity—is digitally shifting its commercial model into a higher gear
Biogen slashes workforce, invests in Tecfidera DTC
From clinical trials to customer planning, digital can speed the biopharma product launch at each step, said Nancy Phelan, BMS head of commercial operations, at last week’s MM&M Leadership Exchange.
Sandoz: Zarxio marketing to be similar to a branded-drug launch
Amy Clarke Luchsinger “thinks that HCPs want both digital and print. The people [she] talks with just want to be able to access information when and where they want it . . .
Five things for pharma marketers to know: Tuesday, August 4
Shire offers to buy Baxalta for $30 billion; CVS reports strong sales in specialty pharmacy; Reuters reports that new drug launches hit 17-year high in 2014
Eyeing big returns, drugmakers ready new hepatitis-C drug launches